Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| type I pneumocyte | 10 studies | 54% ± 18% | |
| retinal cone cell | 7 studies | 58% ± 29% | |
| fibroblast | 6 studies | 33% ± 13% | |
| oligodendrocyte precursor cell | 6 studies | 35% ± 11% | |
| Mueller cell | 5 studies | 65% ± 9% | |
| astrocyte | 5 studies | 51% ± 19% | |
| type II pneumocyte | 5 studies | 23% ± 4% | |
| endothelial cell | 5 studies | 42% ± 23% | |
| retinal bipolar neuron | 4 studies | 28% ± 9% | |
| retinal pigment epithelial cell | 4 studies | 54% ± 19% | |
| glutamatergic neuron | 4 studies | 21% ± 3% | |
| kidney loop of Henle epithelial cell | 4 studies | 35% ± 12% | |
| pericyte | 3 studies | 37% ± 11% | |
| rod bipolar cell | 3 studies | 63% ± 16% | |
| GABAergic neuron | 3 studies | 22% ± 3% | |
| kidney distal convoluted tubule epithelial cell | 3 studies | 43% ± 16% | |
| podocyte | 3 studies | 87% ± 15% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| kidney | 100% | 10029.26 | 89 / 89 | 92% | 7.72 | 828 / 901 |
| thymus | 100% | 8094.86 | 653 / 653 | 88% | 12.73 | 532 / 605 |
| lung | 97% | 3916.52 | 563 / 578 | 56% | 4.23 | 643 / 1155 |
| prostate | 95% | 2392.31 | 232 / 245 | 57% | 1.24 | 286 / 502 |
| adrenal gland | 100% | 3992.85 | 258 / 258 | 21% | 0.88 | 48 / 230 |
| spleen | 99% | 2724.47 | 238 / 241 | 0% | 0 | 0 / 0 |
| muscle | 98% | 4232.32 | 785 / 803 | 0% | 0 | 0 / 0 |
| pancreas | 67% | 513.20 | 221 / 328 | 30% | 0.88 | 54 / 178 |
| ovary | 83% | 1226.85 | 150 / 180 | 8% | 0.23 | 34 / 430 |
| heart | 91% | 1675.07 | 785 / 861 | 0% | 0 | 0 / 0 |
| esophagus | 52% | 607.30 | 757 / 1445 | 24% | 0.63 | 44 / 183 |
| stomach | 49% | 375.57 | 175 / 359 | 16% | 0.41 | 46 / 286 |
| brain | 21% | 143.51 | 558 / 2642 | 41% | 1.38 | 290 / 705 |
| blood vessel | 61% | 2015.70 | 817 / 1335 | 0% | 0 | 0 / 0 |
| bladder | 43% | 388.19 | 9 / 21 | 17% | 0.69 | 86 / 504 |
| uterus | 42% | 408.08 | 72 / 170 | 8% | 0.31 | 37 / 459 |
| intestine | 24% | 573.75 | 233 / 966 | 10% | 0.28 | 51 / 527 |
| lymph node | 0% | 0 | 0 / 0 | 31% | 1.33 | 9 / 29 |
| breast | 18% | 128.85 | 84 / 459 | 9% | 0.18 | 99 / 1118 |
| tonsil | 0% | 0 | 0 / 0 | 22% | 0.61 | 10 / 45 |
| skin | 9% | 79.53 | 170 / 1809 | 8% | 0.22 | 38 / 472 |
| liver | 3% | 17.73 | 7 / 226 | 14% | 0.52 | 57 / 406 |
| peripheral blood | 17% | 404.94 | 158 / 929 | 0% | 0 | 0 / 0 |
| adipose | 9% | 75.14 | 112 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 3% | 0.07 | 2 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0007605 | Biological process | sensory perception of sound |
| GO_0006919 | Biological process | activation of cysteine-type endopeptidase activity involved in apoptotic process |
| GO_0008285 | Biological process | negative regulation of cell population proliferation |
| GO_0009749 | Biological process | response to glucose |
| GO_1905563 | Biological process | negative regulation of vascular endothelial cell proliferation |
| GO_0030198 | Biological process | extracellular matrix organization |
| GO_0038063 | Biological process | collagen-activated tyrosine kinase receptor signaling pathway |
| GO_0007155 | Biological process | cell adhesion |
| GO_0032836 | Biological process | glomerular basement membrane development |
| GO_0016525 | Biological process | negative regulation of angiogenesis |
| GO_0072577 | Biological process | endothelial cell apoptotic process |
| GO_0008015 | Biological process | blood circulation |
| GO_0007166 | Biological process | cell surface receptor signaling pathway |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005576 | Cellular component | extracellular region |
| GO_0062023 | Cellular component | collagen-containing extracellular matrix |
| GO_0005587 | Cellular component | collagen type IV trimer |
| GO_0005788 | Cellular component | endoplasmic reticulum lumen |
| GO_0005783 | Cellular component | endoplasmic reticulum |
| GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
| GO_0005604 | Cellular component | basement membrane |
| GO_0030020 | Molecular function | extracellular matrix structural constituent conferring tensile strength |
| GO_0008191 | Molecular function | metalloendopeptidase inhibitor activity |
| GO_0005198 | Molecular function | structural molecule activity |
| GO_0005178 | Molecular function | integrin binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | COL4A3 |
| Protein name | Collagen type IV alpha 3 chain Collagen alpha-3(IV) chain (Goodpasture antigen) [Cleaved into: Tumstatin] Collagen IV alpha 3 chain |
| Synonyms | |
| Description | FUNCTION: Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen.; FUNCTION: Tumstatin, a cleavage fragment corresponding to the collagen alpha 3(IV) NC1 domain, possesses both anti-angiogenic and anti-tumor cell activity; these two anti-tumor properties may be regulated via RGD-independent ITGB3-mediated mechanisms. FUNCTION: Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen. . |
| Accessions | ENST00000643388.1 ENST00000469504.2 A0A2R8Y6E5 Q01955 A0A2R8Y2F0 H7BXM4 ENST00000396578.8 [Q01955-1] ENST00000304990.8 Q548X1 |